Zealand Pharma

Earnings Release • Oct 31, 2014

Copenhagen, 2014-10-31 09:48 CET (GLOBE NEWSWIRE) -- Copenhagen, 31 October
2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) will announce
its Interim Report for the first nine months of 2014 on Friday, 7 November
2014, in accordance with the company’s financial calendar. The report is
expected to be approved and released in the morning before the start of trading
hours on Nasdaq Copenhagen.

Conference call – Friday, 7 November at 2 pm CET/ 8am EDT

On the day of release, Zealand will host a conference call at 2p CET/ 8am EDT.
On the call, David Solomon, President and Chief Executive Officer, Mats Blom,
Chief Financial Officer, and Hanne Leth Hillman, Vice President and Head of IR
and Corporate Communications, will present the interim report, which will be
followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access +45 3272 8018

UK and international +44 (0) 1452 555131

US (free dial-in) +1 866 682 8490

A live audio cast of the call including an accompanying slide presentation will
be available via the following link, http://www.media-server.com/m/p/awksiczn,
which can also be accessed from the front page of Zealand’s website
(www.zealandpharma.com). Participants in the audio cast are advised to register
approximately 10 minutes before the start.

A replay of the event will be available from the Investor section of Zealand’s
website following the call.

                                  ***

For further information, please contact:

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines, in-house
competences in clinical trial design and management and a therapeutic focus on
cardio-metabolic diseases. The company has a broad portfolio of therapeutic
products – proprietary and partnered.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed world-wide ex-US as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory filing for both products is planned for 2015 ? summer for Lyxumia®
and as early as end 2015 for LixiLan.

Zealand is advancing a pipeline of proprietary, next-generation therapies,
including danegaptide (prevention of Ischemic Reperfusion Injury) in addition
to several preclinical programs. Partnering represents an important component
of strategy to share development risk in large clinical trials, to provide
funding and to commercialize the company’s products. Zealand currently has
global license agreements and partnerships with Sanofi, Boehringer Ingelheim,
Helsinn Healthcare and Lilly,

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma